Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books
 Search for
  Limits Preview/Index History Clipboard Details    
About Entrez
spacer gif
back to About Entrez
back to About Entrez

Text Version

Entrez PubMed
Help | FAQ

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries

Related Resources
Order Documents
NLM Gateway
Consumer Health
Clinical Alerts
PubMed Central

Privacy Policy


1: Ned Tijdschr Geneeskd. 2003 Jul 12;147(28):1370-2. Related Articles, Links

Comment in:
[Withdrawal symptoms in a neonate following exposure to venlafaxine during pregnancy]

[Article in Dutch]

de Moor RA, Mourad L, ter Haar J, Egberts AC.

Afd. Kindergeneeskunde, TweeSteden ziekenhuis, Postbus 90.107, 5000 LA Tilburg.

Withdrawal symptoms occurred in a male neonate after maternal use of venlafaxine for depression during pregnancy. The symptoms were restlessness, hypertonia, jitteriness, irritability and poor feeding. The diagnosis was confirmed by a temporary improvement after administration of a low dose (1 mg) of venlafaxine to the boy. Eventually the symptoms began to decline spontaneously, and ceased after 8 days. Exposure to venlafaxine and other antidepressants which inhibit serotonin reuptake during the third trimester of pregnancy carries the risk of a neonatal withdrawal syndrome.

Publication Types:
  • Case Reports

PMID: 12892015 [PubMed - indexed for MEDLINE]